TCL Archive Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer July 26, 2002
TCL Archive Mortality, Survival Still Improving for Whites, Remain Static Or Decline For Blacks; Largest Survival Increase For Whites In history Of SEER Program June 2, 1989
TCL Archive DCT Board Committee Drawing Up Plans On How To Spend Biological Response Modifiers Money August 31, 1979
TCL Archive House Committee Provides $21 Billion to NCI, Deletes Breast Cancer Earmark, Forward Funding July 2, 1993
